Given the high frequency of activating NOTCH1 mutations in cancers, especially in T-ALL, the inhibition of the γ-secretase complex has represented a rational target to hijack the ligand-independent release of N-ICD for many years. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.